152 results about "Virus types" patented technology

Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and / or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A / Sydney / 5 / 94 (H3N2) and / or avian influenza virus type A / Hong Kong / 1073 / 99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

A system S is defined which is capable of simulating a computer (virtual computer, VC) for the purpose of software performance monitoring. The system is implemented as a set of software modules (SM) that can be exchanged to change the behavior of the VC. The VC is driven by a CPU emulator, and can run any operating system (virtual operating system, VOS) that is supported by the available SM's. The system is designed to log accesses to system resources and the nature of these accesses. The system is particularly useful for determining whether an executable or file contains an unknown virus, with a very low risk of false positives. Detected viruses include encrypted, polymorphic, metamorphic and other virus types.

The present invention relates to reagents and methods for influenza virus detection. These reagents and methods disclosed in the present invention enable simple, rapid, specific and sensitive detection of influenza virus types A and B. These reagents are N-acetylneuraminic acid-firefly luciferin conjugates which can be cleaved by influenza virus neuraminidase.

The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core / E1 region of HCV type 3; and / or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and / or the region spanning positions 4892 to 5292 of the NS3 / 4 region of HCV type 3; and / or the region spanning positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and / or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and / or the coding region of HCV type 4; and / or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and / or HCV type 2 genomes in the above-indicated regions, or the complement thereof.

The invention provides a gene chip detection method for a classical swine fever virus (CSFV), a porcine circovirus virus type 2 (PCV-2), a porcine reproductive and respiratory syndrome virus Europe type (PRRSVE) and a porcine reproductive and respiratory syndrome virus America type (PRRSVA). A gene chip is shown as a probe sequence in the table of the specification. The invention discloses a method for simultaneously detecting three diseases, namely classical swine fever (CSF), a porcine circovirus type 2 (PCV-2) and a porcine reproductive and respiratory syndrome (PRRS) by using the gene chip. By the method, the problems that the conventional detection technology is time-consuming and labor-consuming and has low specificity, or only can be used for detecting a single disease are solved. All probes provided by the invention are synthesized into a connecting amino group at a 5' end, a poly T connecting arm with the length of 15 bp is provided, and a result shows that fixing efficiency is relatively high. By a polymerase chain reaction (PCR) amplification technology with mark primers, various kinds of fluorescent mark deoxyribonucleic acid (DNA) complementary to corresponding probescan be amplified at a time, and the high specificity and sensitivity of nucleic acid hybridization in a solid-liquid phase can be ensured. In addition, by a mark method, detection time is greatly shortened, the cost of chip detection is lowered, and the detection method is more suitable to be popularized in clinical application.

Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

Compositions and methods useful in transgene expression are provided. Herpes simplex virus type 1 thymidine kinase sequences (“TK sequences”) are used to enhance transgene expression in first generation and high capacity adenoviral vectors. An mCMV promoter-driven β-galactosidase-expressing cassette is combined with TK sequences through direct fusion of the cDNA's. β-galactosidase (transgene) expression is enhanced independent of adenoviral vector selection. Methods of enhancing transgene expression employing the inventive adenoviral vectors are provided, along with pharmaceutical preparations comprising the inventive vectors and kits for enhanced transgene expression.

The present invention relates to genetic markers for discrimination and detection of viruses causing infectious aquatic organism diseases, and a method of discriminating and detecting the viruses using the same, and more particularly to a method for discriminating or detecting viruses causing infectious aquatic organism diseases, the method comprising: selecting and amplifying a DNA nucleotide sequence encoding a gene specific for viral hemorrhagic septicemia virus (VHSV), red sea bream iridovirus (RSIV) or infectious spleen and kidney necrosis virus (ISKNV), which is a virus causing red sea bream iridovirus disease, or Koi herpesvirus (KHV); hybridizing a peptide nucleic acid (PNA) that specifically recognizes the amplification product; controlling the temperature of the hybridization product to obtain a temperature-dependent melting curve; and discriminating the viral type or detecting whether or not fish would be infected with the viral type by analyzing the obtained melting curve to determine a melting temperature.

The invention discloses a Coxsackie virus type A16 (CA16) real-time fluorescent nucleic acid isothermal amplification detection kit comprising reagents such as a capturing probe, CA16 amplification primers T7 primer and nT7 primer, a CA16 detection probe, M-MLV reverse transcriptase, T7 RNA polymerase, and the like. The kit can be used for detecting CA16 RNA in throat swab or stool, and has the characteristics of high specificity, high sensitivity (reaching 10copies / reaction), low pollution (amplification product RNA can be easily degraded under natural environment), and fast detection (conventionally detection can be finished within 60min). The kit can perform important effect in clinical diagnosis of CA16 early-stage infection, and can be widely applied.

Provided are non-competitive internal controls for use in nucleic acid tests (NATs), which are obtained from the organisms Methanobacterium thermoautrophicum (MET) and Zea mays (Corn). The non-competitive internal controls have utility in DNA and RNA NATs selected from Influenza A, Influenza B, parainfluenza viruses 1 to 4 (PIV-1 to PIV-4), respiratory syncytial virus type A (RSV A), RSV B, human metapneumovirus (hMPV), Chlamydia trachomatis (CT), and Neisseria gonorrhea (GC), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Immunodeficiency Virus I (HIV-1), and Severe Acute Respiratory Syndrome (SARS).

Methods and kits for immunizing animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2 are provided. The protective immune response elicited by the methods and kits is characterized by robust humoral, cellular, and mucosal immunity. In particular, a heterologous immunization method comprising a priming DNA vaccine encoding an antigen and a boosting protein vaccine, in which the protein form of the antigen is encapsulated in liposomes is provided. Methods of preventing primary acute, latent and recurrent viral infections, such as that caused by HSV-2 virus, and methods of providing passive protective immunity against a viral pathogen such as HSV-2 virus to a mammal are also disclosed.